This entry summarizes a study report from European Urology comparing two management strategies for recurrent high-grade non–muscle-invasive bladder cancer: radical cystectomy versus bladder-sparing therapy. The extract title indicates a twelve-month results horizon from the CISTO study, with authors Gore, Wolff, Nash, and colleagues.
The available content specifies only authorship, title, and journal source; there are no details provided on methods, patient selection, endpoints, comparative outcomes, adverse events, or statistical results. Therefore, the precise findings, effect sizes, and conclusions cannot be stated from the supplied text.
It remains uncertain whether the study demonstrated equivalence, superiority, or noninferiority of bladder-sparing therapy relative to radical cystectomy at twelve months, or whether specific metrics (recurrence, progression, survival, toxicity, quality of life) were reported. If additional content from the article (methods, results, or conclusions) can be provided, a concise clinical-Editor summary can be composed with explicit data points.
As presented, the gist is limited to bibliographic metadata without substantive outcome data.
European Urology published a clinical update in Research Highlights on 24 Feb 2026.
The item focuses on Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non–muscle-invasive Bladder Cancer.
Review the original article for the full source wording and details.